Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 86Gastrointestinal 40Sarcoma 22Breast 20Thoracic 16Endocrine 11CNS 11Lymphoid 7Gynecologic 7NET 6Tumor-Agnostic 5Head & Neck 5Other solid neoplasm 4Other hematologic neoplasm 4Dermatologic 3Plasma cell 2Myeloid 2

Conditions

Multiple Myeloma 2Lymphoma 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Sunitinib × Plasma cell × Clear all
NCT06390826 2026-05-28

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 10 charts
LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00514137 2014-05-28

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
13 enrolled 7 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡